S. Subramaniam et al., ERYTHROCYTE ANTIOXIDANT ENZYME-ACTIVITY IN CMF TREATED BREAST-CANCER PATIENTS, Cancer biochemistry biophysics, 14(3), 1994, pp. 177-182
Most of breast cancer patients are treated with CMF, which is a combin
ation of three anticancer agents, cyclophosphamide, methotrexate and 5
-fluorouracil. Metabolites of CMF induce lipid peroxidation by inactiv
ating the antioxidant enzymes, thereby rendering the system inefficien
t in management of the free radical aback. Acrolein and phosphoramide
mustard are the metabolites of cyclophosphamide which are among the ca
usative agents which reduce the activity of superoxide dismultase, cat
alase, glutathione peroxidase, glutathione reductase, glutathione-S-tr
ansferase and glucosed-6-phosphate dehydrogenase in erythrocytes of CM
F treated breast cancer patients.